Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts At Tertiary Care Hospital in Karachi.

Early Phase 1

• Conditions: Cutaneous Warts
• Interventions: Drug: Furosemide

• Registration Number: NCT06821594
• Lead Sponsor: Jinnah Postgraduate Medical Centre

Brief Summary

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Detailed Description

Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Study Timeline

• Status Verified: 2024-11
• Study First Submitted: 2025-02-06
• Study First Submitted QC: 2025-02-06
• Last Update Submitted: 2025-02-06
• Study First Posted: 2025-02-12
• Last Update Posted: 2025-02-12
• Study Start: 2025-04-01
• Primary Completion: 2025-08-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Patients presenting with greater than or equal to two warts
2. Either gender.
3. Age 18 - 60 years. -

Exclusion Criteria

1. Pregnant or lactating women.
2. Patient not giving informed consent.
3. Patient received any treatment in the last 3 months period.
4. Patient with acute illness and immuno-suppressive disease.
5. Patient taking immuno-suppressive drugs.
6. Patient having hypersensitivity to any investigational medicine.
7. Patient having cutaneous warts on face and genitals.
8. Patient having cardiovascular disease.
9. Patient having renal disease. -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients	Furosemide	Patients with age between 18-60 years having more than two cutaneous warts will be given combined intralesional furosemide (20mg/2ml) and digoxin (0.5mg/2ml) 0.2 ml at the base of warts once weekly for five weeks

Primary Outcome Measures

Name	Time	Method
Size of cutaneous wart	5 weeks	Change in the dimensions of cutaneous wart assessed by Physician's wart assessment scale weekly and through photographs taking at the start and end of the study.

Trial Locations

Locations (1)

Jinnah Postgraduate Medical Centre; 🇵🇰 Karachi, Sindh, Pakistan